Loading…
MARKETS
TOOLS
LEARN
Equiscale · Syntellia LLC
Guardian Pharmacy Services, Inc., a pharmacy service company, provides a suite of technology-enabled services to help residents of long-term health care facilities (LTCFs) in the United States. The company's individualized clinical, drug dispensing, and administration capabilities are used to serve the needs of residents in lower acuity LTCFs, such as assisted living facilities, behavioral health facilities, and group homes. Its Guardian Compass includes dashboards created using data from its data warehouse to help its local pharmacies plan, track, and optimize their business operations; GuardianShield Programs for LTCFs; Order Entry QA Analyzer, which utilizes real-time rules- engine technology to examine prescriptions and detect omissions and/or errors before they become a customer service problem; and Medication Spend Analyzer to break down the monthly drug spending for each of the LTCFs. Guardian Pharmacy Services, Inc. was founded in 2003 and is headquartered in Atlanta, Georgia.
Rule-based from financial data. Not advice.
5-year financial trends. Figures in USD millions.
Latest fiscal year: 2025
Year-by-year revenue, profitability, and cash flow (USD millions, last 10 years)
| Year | Revenue | EBITDA | Net Profit | FCF | ROE | Rev Growth 1Y | NP Growth 1Y |
|---|---|---|---|---|---|---|---|
| 2025 | $1.4B | $96M | $49M | $81M | 23.9% | 17.9% | -156.4% |
| 2024 | $1.2B | $-43M | $-87M | $42M | -61.2% | 17.4% | -465.2% |
| 2023 | $1.0B | $59M | $24M | $56M | 84.7% | 15.1% | -32.5% |
| 2022 | $909M | $68M | $35M | $32M | 82.9% | - | - |
Income statement, balance sheet, and cash flow as reported
Consolidated Figures in USD Millions.
| Metric | 2021 | 2022 | 2023 | 2024 | 2025 |
|---|---|---|---|---|---|
| Total Revenue | - | 908.91 | 1,046.19 | 1,228.41 | 1,448.68 |
| Operating Revenue | - | 908.91 | 1,046.19 | 1,228.41 | 1,448.68 |
| Cost Of Revenue | - | 723.04 | 837.88 | 984.04 | 1,155.97 |
| Gross Profit | - | 185.87 | 208.31 | 244.37 | 292.72 |
| Operating Expense | - | 133.88 | 167.36 | 307.29 | 220.02 |
| Selling General And Administration | - | 133.88 | 167.36 | 307.29 | 220.02 |
| Total Expenses | - | 856.92 | 1,005.25 | 1,291.33 | 1,375.98 |
| Operating Income | - | 51.99 | 40.95 | -62.92 | 72.70 |
| Total Operating Income As Reported | - | 51.99 | 40.95 | -62.92 | 72.70 |
| EBITDA | - | 68.15 | 58.81 | -43.43 | 96.42 |
| Normalized EBITDA | - | 68.15 | 58.81 | -43.43 | 96.42 |
| EBIT | - | 51.59 | 40.58 | -63.20 | 74.09 |
| Interest Expense | - | 1.93 | 2.86 | 3.28 | 0.66 |
| Net Interest Income | - | -1.93 | -2.86 | -3.28 | -0.66 |
| Other Non Operating Income Expenses | - | -0.40 | -0.37 | -0.28 | 1.39 |
| Other Income Expense | - | -0.40 | -0.37 | -0.28 | 1.39 |
| Interest Expense Non Operating | - | 1.93 | 2.86 | 3.28 | 0.66 |
| Net Non Operating Interest Income Expense | - | -1.93 | -2.86 | -3.28 | -0.66 |
| Pretax Income | - | 49.66 | 37.72 | -66.48 | 73.42 |
| Tax Provision | - | - | 0 | 4.56 | 24.46 |
| Tax Rate For Calcs | - | 0 | 0 | 0 | 0 |
| Tax Effect Of Unusual Items | - | 0 | 0 | 0 | 0 |
| Net Income Continuous Operations | - | 49.66 | 37.72 | -71.03 | 48.96 |
| Net Income From Continuing And Discontinued Operation | - | 35.42 | 23.90 | -87.29 | 49.22 |
| Net Income From Continuing Operation Net Minority Interest | - | 35.42 | 23.90 | -87.29 | 49.22 |
| Net Income | - | 35.42 | 23.90 | -87.29 | 49.22 |
| Net Income Common Stockholders | - | 35.42 | 0 | -110.05 | 49.22 |
| Net Income Including Noncontrolling Interests | - | 49.66 | 37.72 | -71.03 | 48.96 |
| Normalized Income | - | 35.42 | 23.90 | -87.29 | 49.22 |
| Diluted NI Availto Com Stockholders | - | 35.42 | 0 | -110.05 | 49.22 |
| Basic Average Shares | - | 60.84 | 60.84 | 62.01 | 62.39 |
| Diluted Average Shares | - | 60.84 | 60.84 | 62.01 | 63.30 |
| Reconciled Depreciation | - | 16.56 | 18.23 | 19.77 | 22.34 |
| Reconciled Cost Of Revenue | - | 723.04 | 837.88 | 984.04 | 1,155.97 |
| Minority Interests | - | -14.24 | -13.82 | -16.25 | 0.26 |
| General And Administrative Expense | 13.03 | - | - | - | - |
| Salaries And Wages | 13.03 | - | - | - | - |
| Other Operating Expenses | - | -3.38 | - | - | - |
| Selling And Marketing Expense | 118.09 | 137.26 | - | - | - |
| Otherunder Preferred Stock Dividend | - | - | 23.90 | 22.76 | 0 |
Healthcare sector peers, ranked by market cap
| Company | Ticker | Market Cap | P/E | P/B | ROE | EV/EBITDA |
|---|---|---|---|---|---|---|
| Guardian Pharmacy Services, Inc.this co. | GRDN | $2.6B | 52.49 | 12.56 | 23.9% | 26.50 |
| Soleno Therapeutics, Inc. | SLNO | $2.8B | 132.26 | 6.14 | 4.6% | 96.72 |
| Arcutis Biotherapeutics, Inc. | ARQT | $2.7B | -170.10 | 14.49 | -8.5% | 1582.53 |
| Disc Medicine, Inc. | IRON | $2.7B | -12.80 | 3.67 | -28.7% | -12.77 |
| Definium Therapeutics, Inc. |
| 2021 |
| - |
| - |
| - |
| - |
| - |
| - |
| - |
| DFTX |
| $2.7B |
| -14.59 |
| 8.07 |
| -55.3% |
| -13.82 |
| Alumis Inc. | ALMS | $2.6B | -10.68 | 8.63 | -80.8% | -5.66 |
| Tarsus Pharmaceuticals, Inc. | TARS | $2.6B | -39.09 | 7.56 | -19.3% | -45.85 |
| IDEAYA Biosciences, Inc. | IDYA | $2.6B | -22.58 | 2.51 | -11.1% | -16.04 |
| Heartflow, Inc. | HTFL | $2.5B | -21.27 | 8.26 | -38.8% | -26.44 |
| Peer Median | - | -17.93 | 7.81 | -24.0% | -13.30 | |
Historically, Nov has averaged the highest return (+21.8%); Dec the lowest (-8.0%).
| Year | Jan | Feb | Mar | Apr | May | Jun | Jul | Aug | Sep | Oct | Nov | Dec |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| 2026 | +0.4%Neutral MonthJan 2026: +0.37% | +11.0%Positive MonthFeb 2026: +10.96% | +12.4%Positive MonthMar 2026: +12.38% | -1.5%Neutral MonthApr 2026: -1.49% | +4.4%Positive MonthMay 2026: +4.42% | +8.1%Positive MonthJun 2026: +8.08% | -5.6%Negative MonthJul 2026: -5.59% | -3.9%*Negative MonthAug 2026: -3.95% | — | — | — | — |
| 2025 | +12.6%Positive MonthJan 2025: +12.59% | -12.3%Negative MonthFeb 2025: -12.32% | +6.3%Positive MonthMar 2025: +6.30% | +17.8%Positive MonthApr 2025: +17.78% | -15.5%Negative MonthMay 2025: -15.46% | +0.7%Neutral MonthJun 2025: +0.66% | -1.9%Neutral MonthJul 2025: -1.92% | +26.4%Positive MonthAug 2025: +26.41% | -0.7%Neutral MonthSep 2025: -0.72% | +6.9%Positive MonthOct 2025: +6.90% | +4.4%Positive MonthNov 2025: +4.42% | +2.8%Positive MonthDec 2025: +2.77% |
| 2024 | — | — | — | — | — | — | — | — | — | +6.6%Positive MonthOct 2024: +6.61% | +39.3%Positive MonthNov 2024: +39.25% | -18.8%Negative MonthDec 2024: -18.77% |
| Avg±SD |
Each cell is the percentage change in closing price from the end of the prior month to the end of this month. The bottom row shows the average return for that calendar month across the selected years, plus or minus one standard deviation — the range that historically contained roughly two-thirds of outcomes. Past monthly patterns are not a forecast of future returns.
This aggregates every month by calendar position — all Januaries together, all Februaries together, and so on — to show whether a given month has leaned positive or negative historically. ‘Simple’ counts each month as +1 or −1. ‘Weighted’ gives larger moves more influence: +2 above +10%, −2 below −10%. With only 3 years of history for this asset, each month’s score reflects a small number of observations — read it as a historical tendency, not a reliable seasonal pattern.
This tracks a running tally across the asset’s full price history: each month adds or subtracts based on whether it was positive or negative. A rising line means more positive months than negative so far; a flattening or falling line means recent months have leaned negative. This measures historical month-to-month consistency, not expected future performance.
Year-to-date return is calculated by dividing each day’s closing price by the price on January 1st of that year (or the asset’s first available price if it began trading mid-year). The custom average line shows the mean YTD return at each calendar day across the selected years. The standard deviation band shows the range within which returns have historically fallen — at 1 SD, roughly two-thirds of years; at 2 SD, roughly 95%. Past year-to-date patterns do not predict future returns. The average and standard deviation band are computed from the year set chosen in “Average from”, which is independent of which year lines are displayed. The current in-progress year is excluded from these calculations, since a partial year is not comparable to complete ones. Election-cycle groupings follow the US presidential calendar and are offered only for US and crypto assets.
